Vision Medicals Completes RMB 300 Million Series D Financing to Strengthen Leadership in Infectious Disease Precision Diagnostics

VCBeat has learned at the earliest opportunity,VISION MEDICALS Announces Completion of RMB 300 Million Series D Financing, Continuing to Lead the Field of Precision Medicine for Infectious DiseasesRecently, VISION MEDICALS announced the completion of its Series D financing round, with a total amount of RMB 300 million, continuing to lead the track of precision medicine for infectious diseases. This round was led by Boyu Capital, with continued support from previous lead investors and other existing shareholders, including CDH VGC.This marks VISION MEDICALS’ second multi-hundred-million-yuan financing round this year, following its C-round raise of RMB 200 million in early February, underscoring continued favor from top-tier investors. The proceeds will be primarily allocated to strategic initiatives, including product research and development, upgrades, medical device regulatory approvals, and supply chain expansion.

VISION MEDICALS, established in 2018, specializes in genetic diagnostics and precision medicine for infectious diseases. The company has built an AI-driven diagnostic system for infectious diseases based on genomics, radiomics, and electronic medical records (EMR), providing comprehensive solutions for precise clinical diagnosis of infections. VISION MEDICALS has established a R&D center, medical testing laboratories, and a GMP-compliant production base for in vitro diagnostic reagents, covering over 10,000 square meters. It has also set up medical testing laboratories and branch offices in multiple cities, including Beijing, Shanghai, Nanjing, Zhengzhou, and Chengdu. Over the past three years, the company has achieved fruitful research outcomes, publishing more than 20 high-impact SCI papers, filing 50 invention patents (with 10 granted), and registering nearly 20 software copyrights. Since its inception, as a national high-tech enterprise, VISION MEDICALS has won numerous national honors and government funding support. It has been recognized among the Top 50 Unicorns in the New Healthcare Industry, listed as a Potential Unicorn Enterprise in China, ranked among the Top 50 Pioneer Enterprises in the New Economy of the Guangdong-Hong Kong-Macao Greater Bay Area, and has been included in the "China Future Healthcare 100" list for three consecutive years.

In terms of business performance, VISION MEDICALS has provided services to more than 1,400 medical institutions, accumulated a large-sample dataset of over 150,000 cases of pathogen metagenomics, and jointly established pathogen metagenomics platforms with top-tier hospitals in China, including Peking Union Medical College Hospital, Chinese PLA General Hospital, Wuhan Tongji Hospital, The First Affiliated Hospital, Zhejiang University School of Medicine, and Shanghai Children's Medical Center.Mr. Li Yongjun, Founder and CEO of VISION MEDICALSVISION MEDICALS has experienced rapid growth over the past three years, expanding its team to nearly 600 employees and attracting talent and elites from comprehensive fields such as pathogen biology, genomics, and the clinical management of infectious diseases. In January 2020, at the onset of the COVID-19 pandemic, VISION MEDICALS participated in the initial discovery of the novel coronavirus using its innovative pathogen metagenomic next-generation sequencing (mNGS) technology. In 2021, VISION MEDICALS co-hosted the Summit on Precision Medicine for Infectious Diseases with the Chinese Academy of Medical Sciences, established the China mNGS Interpretation Alliance, and contributed to the publication of two expert consensus statements on mNGS in the Chinese Journal of Laboratory Medicine. Over the next three years, VISION MEDICALS will focus on precision medicine for infectious diseases, advancing both its Independent Clinical Laboratory (ICL) testing services and its dual-line model of IVD instruments and reagents to drive industry development and strengthen its leading market position.

In terms of product platform layout, VISION MEDICALS has always been customer-need-oriented, taking into account market changes and compliance requirements.Mr. Wang Xiaorui, Founder and COO of VISION MEDICALSIt was announced that earlier this year, VISION MEDICALS made further strides as its self-developed “Pathogenic Microorganism Sequencing Data Analysis Software” successfully obtained a medical device registration certificate in China. Among the products currently holding such certificates, this software analyzes and detects the widest variety of pathogens and covers fungi and parasites not detected by other similar products, thereby offering greater clinical significance. Regarding future product planning, Wang Xiaorui further stated that VISION MEDICALS will continue to deepen its presence in the field of precision infectious disease medicine, expanding from next-generation sequencing (NGS) metagenomic technology to technical platforms such as CRISPR-based POCT testing and high-throughput fully automated real-time quantitative PCR testing, while actively advancing the regulatory submission and approval processes for multiple diagnostic instruments and test kits.

In terms of technological innovation and quality control,Dr. Teng Xu, Founder and CTO of VISION MEDICALSVISION MEDICALS has assembled an international, diverse, and highly focused team of talents, continuously dedicating itself to the innovation and refinement of precise pathogen diagnostic technologies, establishing itself as an industry leader in technology and quality control capabilities. Earlier this year, VISION MEDICALS’ clinical laboratory became the only company to achieve a perfect score, successfully passing the inaugural national external quality assessment for metagenomic next-generation sequencing (mNGS) in lower respiratory tract infections, organized by the National Center for Clinical Laboratories under the National Health Commission. Discussing future technological and product development, Dr. Xu Teng stated: “Building on traditional pathogen metagenomics, we have prominently launched IDseq Ultra, a novel product based on pathogen-capture metagenomics. This solution increases the detection sensitivity for clinically significant pathogens by two orders of magnitude while retaining comprehensive coverage of rare and emerging pathogens, and enables more in-depth analysis of antibiotic resistance genes and virulence factors. VISION MEDICALS will continue to stay at the forefront, leading technological advancement.”

Looking ahead, VISION MEDICALS will focus on precision medicine for infectious diseases, leveraging its core technologies—pathogen metagenomic next-generation sequencing (mNGS) diagnostics and rapid diagnostic tools based on CRISPR-Cas12/13 gene editing. The company will actively expand into other methodologies and technical platforms, striving to provide comprehensive, precise diagnostic solutions for infection across diverse application scenarios, including clinical departments, laboratory medicine units, and centers for disease control and customs agencies.

Boyuu Capital is an asset management firm founded in 2011, with multiple business lines including private equity, secondary markets, real estate, and venture capital. It focuses on four key sectors: consumer retail, financial services, healthcare, and TMT (Technology, Media, and Telecom). The firm is committed to investing in outstanding companies within high-growth industries, consistently delivering superior long-term returns to its investors.